incidence and epidemiology
Thymic epithelial tumours represent a heterogeneous group of rare thoracic cancers, with reported annual incidence ranging from 1.3 to 3.2 per million [1] . Thymic epithelial tumours are classified according to the World Health Organization (WHO) histopathological classification, which distinguishes thymomas from thymic carcinomas.
thymomas Thymomas are further subdivided into different types (called A, AB, B1, B2, B3 and rare others) based upon the morphology of epithelial tumour cells, the relative proportion of the non-tumoural lymphocytic component (decreasing from type B1 to B3) and resemblance to normal thymic architecture (Table 1) [2, 3] . The term 'benign thymoma' should be avoided. Thymomas are far more frequent than thymic carcinomas, which have an incidence of 0.2 to 0.5 per million [3] .
thymic carcinomas
Thymic carcinomas are similar to their extrathymic counterpart, the most frequent subtype being squamous cell carcinoma. Neuroendocrine tumours may occur in the thymus, and will not be discussed in these guidelines; while localised primary thymic neuroendocrine tumours may benefit from surgical resection, similar to other thymic carcinomas, the prognosis is poor given frequent recurrences; for recurrent, advanced and metastatic tumours, the management actually follows that of extra-thoracic neuroendocrine tumours.
epidemiology
Mean age at diagnosis is 50-60 years of age, but thymic tumours may actually be diagnosed in children as well as in elderly patients. There is no consistent gender predilection in thymomas overall, even if a slight female preponderance has been reported for type A, AB and B1 subtypes in most studies, and a male predominance in carcinomas [2] [3] [4] [5] [6] [7] .
No environmental or infectious factors have been demonstrated to play a role in the pathogenesis of thymic epithelial tumours. Reports on development of thymoma after radiation, solid-organ transplantation and immunosuppression, including the context of human immunodeficiency virus infection, are rare; differential diagnosis with thymic rebound hyperplasia may be discussed in this setting (see below).
Genetic risk factors, such as multiple endocrine neoplasia 1 (MEN1), may influence the development of thymomas, as well as thymic carcinoids, given their reported familial occurrence as well as their association with cancer susceptibility syndromes [8] .
Moreover, extrathymic haematopoietic cancers (mostly diffuse large B-cell lymphoma and leukaemia) and a broad spectrum of solid cancers (stomach, pancreas, colon and thyroid) have been reported to occur more frequently in thymoma patients, particularly subsequently [9] . This might be related to a shared unknown oncogenic trigger, a thymoma-associated immune deficiency or (less likely) to adverse effects of treatments.
diagnosis imaging and laboratory tests
Standard imaging for thymic tumours is i.v. contrast-enhanced computed tomography (CT) scan of the thorax, allowing a complete exploration of the mediastinum and the pleura from the apex to the costodiaphragmatic recesses [IV, A] . CT is equal or superior to magnetic resonance imaging (MRI) for the diagnosis of mediastinal anterior masses, except in the setting of cystic lesions [IV, B] [10] .
One-third of patients with thymoma present with autoimmune disorders (Table 2) , mainly myasthenia gravis which is particularly common in type AB, B1 and B2 thymomas and almost always associated with anti-acetylcholine receptor antibodies (Table 1 ) [11] . Other frequent disorders include pure red cell aplasia (5% of cases) and hypogammaglobulinaemia (Good syndrome: 5% of cases) [12] .
In addition to recording a complete history and conducting a full clinical examination (looking especially at neurological signs), systematic immunological check-up is recommended when a diagnosis of thymic epithelial tumour is suspected, including complete blood cells count with reticulocytes and serum protein electrophoresis, as well as anti-acetylcholine receptor and anti-nuclear antibodies tests [V, A] . Indeed, frequent immune disorders associated with thymoma may impact the course of all therapeutic interventions including surgery, radiotherapy as well as chemotherapy.
diagnosis approach
The diagnosis of any thymic epithelial tumour relies on making the differential diagnosis with other anterior mediastinal tumours and non-malignant thymic lesions [13] . CT is the imaging modality of choice. The need for pretreatment biopsy depends on the resectability of the tumour [14] [15] [16] .
Thymic epithelial tumours are the most frequent cause of anterior mediastinal mass, accounting for 35% of cases; the most relevant differential diagnoses include lymphomas (Hodgkin's or non-Hodgkin's) in ∼25% of cases and germ-cell tumours (teratoma or seminoma/non-seminomatous tumours) in ∼20% of cases [13] . Thymic carcinoma must be differentiated from lung carcinoma, as well as from rarer entities, such as NUT carcinomas [17] .
Clinical judgement based on a complete history and physical, especially neurological, examination, correlated with laboratory tests and radiological features, helps to develop a presumptive diagnosis. Thymoma is the most likely diagnosis when facing a mediastinal mass associated with one of the above autoimmune diseases, while thymic carcinoma patients typically have unspecific local symptoms [IV, A]. Lymphoma may be considered in case of rapid onset of B-signs, coexistent lymphadenopathy or elevated lactate dehydrogenase. Teratoma usually shows a heterogeneous morphology on imaging, with fat and cystic pattern [18] . Seminomas and non-seminomatous germ-cell tumours may be large and have a fulminant onset. Elevated serum β-human chorionic gonadotropin may be observed in seminomas, along with elevated alphafetoprotein in non-seminomatous germ-cells tumours.
Differentiating thymic malignancy from hyperplasia or non-involuted thymus may be challenging. Thymic rebound hyperplasia should be considered after stress, injuries, chemotherapy, radiotherapy, anti-hormonal treatment or corticosteroids. Thymic lymphoid hyperplasia is most commonly observed in myasthenia gravis, but also in the setting of hyperthyroidism, connective tissue or vascular disease. CT I  II  III  IVA  IVB   Type A  12% (3%-26%)  15% (0%-35%)  60%  31%  8%  <1%  <1%  Type AB  28% (15%-43%)  20% (5%-42%)  67%  26%  6%  1%  1%  Type B1  18% (6%-53%)  40% (5%-69%)  50%  37%  9%  3%  1%  Type B2  26% (8%-41%)  50% (23%-73%)  32%  29%  28%  8%  3%  Type B3  16% (3%-35%)  50% (25%-65%)  19%  36%  27%  15%  3%  Carcinoma  18% (1%-28%)  <5%  10%  10%  45%  15%  20% Data are based on references [5] [6] [7] [8] . 18-Fluorodeoxyglucose positron emission tomography (PET) scan is generally not recommended to assess thymic masses [IV, C] . Standard uptake values may be higher in type B3 thymomas and thymic carcinomas; however, thymic hyperplasia may also present with hypermetabolism [21] . PET scan is optional in the case of tumours with aggressive histology and an advanced stage to complete the staging work-up or further characterise lesions suspicious for recurrences.
need for biopsy
Pretreatment biopsy is not required if the diagnosis of thymic tumour is highly probable and upfront surgical resection is achievable (see below, definition of resectability) [IV, E] . Biopsy is required in all other clinical situations [IV, A]: approaches may consist of percutaneous core-needle biopsy or incisional surgical biopsy through mediastinotomy or mini-thoracotomy, with sensitivity rates ranging from 40% to 93% [22] . Biopsies that are deep and multiple are preferred. Pleural spaces should be respected to avoid tumour cell seeding. Fine-needle aspiration is generally not recommended [IV, D].
thymomas. Although designed for surgical resection specimens, the WHO classification may be used for small biopsies [V, A]. However, thymoma subtyping on small biopsies is usually not needed for the therapeutically relevant distinction between lymphoma and solid tumour. In any case, diagnostic discrepancies between core-needle and resection specimen histology can be anticipated, given the frequent occurrence of histological tumour heterogeneity that may be missed due to sampling error [23] . The recent proposal of major and minor morphological and immunohistochemical criteria to better individualise each thymic epithelial tumour entity aims at addressing those issues, and has been integrated in the revised WHO classification [3, 24] . Immunohistochemical markers may be helpful, including cytokeratins and p63 expression for normal and neoplastic epithelial cells, and terminal deoxynucleotidyl transferase expression in immature T cells (usually observed in types AB, B1, B2 and B3 thymomas, and absent in carcinomas and type A thymomas) [3] . thymic carcinomas. Immunohistochemistry with anti-CD117/ KIT and anti-CD5 antibodies helps to establish the thymic origin in ∼80% of mediastinal carcinomas [V, A]. Since these markers are not absolutely specific, correlation with the clinical setting is always recommended, and is mandatory in the subset of 20% of thymic carcinomas without expression of CD117/KIT and CD5 [3] .
In thymic tumours showing more than one histological pattern, each component should be listed (starting with the predominant one) and be quantified in 10% increments; a thymic carcinoma component should always be mentioned first [V, C] . In case of difficult diagnosis, it is recommended to consult a second pathologist or refer the case to a thymic tumour pathology panel.
staging and risk assessment staging Thymic epithelial tumours are routinely staged according to the Masaoka-Koga staging system (Table 3) [III, A] [25] [26] [27] , which is correlated with overall survival (OS) [4, 28, 29] . Masaoka-Koga staging is a surgical pathology system that is assessable only after surgical resection of the tumour. A typical feature of thymic epithelial tumours is the correlation between the WHO classification and stage at diagnosis (Table 1) , which may explain its reported prognostic value [4] [5] [6] (Figures 1-3) .
The International Association for the Study of Lung Cancer (IASLC) Staging Prognostic Factors Committee, together with the International Thymic Malignancy Interest Group (ITMIG), recently proposed a Tumour-Node-Metastasis (TNM)-based staging system for thymic malignancies, based on OS analyses of a retrospective international database of more than 10 000 cases (Table 4 ) [30] . The TNM-based approach has the advantage of being more appropriate both for thymoma and thymic carcinomas, which present with a higher propensity toward nodal and distant metastatic invasion. The IASLC/ITMIG TNM system of thymic tumours will be incorporated as the official thymic tumour staging system into the 8th edition of the TNM staging system of thoracic malignancies expected in 2016-2017. From our standpoint, the Masaoka-Koga staging should remain the standard for the routine management of patients, pending the approval of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) [III, A] . Moreover, given the major switch that the TNM system represents and the limited amount of fair level of evidence data to support our current treatment strategies (especially postoperative radiotherapy), the value of the TNM system to drive the therapeutic strategy has to be assessed. Correlative clinical data based on this system may be encouraged in a research setting.
The assessment of resectability is mostly based on the surgeon's expertise; it is recommended to discuss indications for surgery in a multidisciplinary tumour board setting [V, B] . There is no recognised clinical staging system, and the treatment strategy for thymic epithelial tumours is primarily based on whether the tumour may be resected upfront or not [IV, A], as complete resection has been identified as the most consistent and significant prognostic factor of disease-free survival and OS [5, 6, 29] . Correlation between clinical and surgical pathology stage is higher in advanced stages, given the identification of vessel invasion, enlarged lymph nodes, pleural/ pericardial lesions or even systemic metastases [28] . Preoperative CT findings reported to be associated with tumour invasiveness and/or completeness of resection include: tumour size (>5/7/8 cm, depending on studies), lobulated or irregular contours, calcifications, infiltration of surrounding fat, lung infiltration, great vessel invasion or encirclement [31] [32] [33] . The new TNM staging may even provide more help in formalising resectability: T1-3 level of invasion refers to structures amenable to surgical resection, while T4 level of invasion includes unresectable structures (Table 4) . -Microscopic invasion of the mediastinal pleura (either partial or penetrating the elastin layer) -Microscopic invasion of the pericardium (either partial in the fibrous layer or penetrating through to the serosal layer) -Microscopically confirmed direct penetration into the outer elastin layer of the visceral pleura or into the lung parenchyma -Invasion into the phrenic or vagus nerves (microscopically confirmed) -Invasion into or penetration through major vascular structures (microscopically confirmed) -Adherence (i.e. fibrous attachment) of lung or adjacent organs only if there is mediastinal pleural or pericardial invasion (microscopically confirmed)
Stage IVA Pleural or pericardial metastasis -Microscopically confirmed separate nodules in the visceral or parietal pleural, pericardial or epicardial surfaces
Stage IVB Lymphogenous or haematogenous metastasis -Lymphogenous or haematogenous metastasis 53% (32%-73%) 57% (24%-90%) 54% (37%-67%) Prognostic assessment is challenging, as the impact of tumour stage and histology on OS is superseded by the achievement of a complete resection in reported series [4] [5] [6] [7] [28] [29] [30] . Moreover, depending on stage, up to 50%-60% of patients actually do not die of progression of the thymic tumour [34] . Autoimmune disorders have been reported as the cause of death in 25% of thymomas, especially those with early-stage tumours. The evolution of these alterations, which are related to the abnormal intrathymomatous selection of constitutively autoreactive lymphocytes, does not parallel that of the tumour. This is contrary to what is observed in paraneoplastic syndromes that are caused by tumour cell-derived cytokines or hormones or by cross-reactive antibodies. The management of autoimmune syndromes will not be discussed in these guidelines, but should be integrated in the oncological management of these patients [V, A].
management of resectable disease
The treatment strategy is based on the resectability of the tumour. If complete resection is deemed to be achievable upfront, as it is the case in Masaoka-Koga stage I/II and some stage III tumours (classified as stage I, II, IIIA/T3 in the IASLC/ITMIG TNM proposed system), surgery represents the first step of the treatment [IV, A], possibly followed by postoperative radiotherapy and, less frequently, chemotherapy (Table 5) .
surgical principles
The standard approach is median sternotomy [IV, A], which allows the wide opening of the mediastinum and both pleural cavities, followed by evaluation of macroscopic capsular invasion, infiltration of perithymic and mediastinal fat, peritumoural and pleural adherences and involvement of surrounding structures [14, 15, 35, 36] . Generally, complete thymectomy Lymphadenectomy has historically rarely been carried out after resection of thymic tumours. The new IASLC/ITMIG TNM staging system of thymic tumours, however, leads to the recommendation that locoregional lymphoadenectomy should be carried out during resection of all types of thymic tumours. A proposed nodal map is available from ITMIG [41] . The proposed N descriptor in the staging system includes:
• anterior region (N1), which involves the anterior mediastinal nodes ( prevascular, para-aortic, ascending aorta, superior and inferior phrenic and supradiaphragmatic) and the anterior cervical nodes (low anterior cervical); and Extension into the mediastinal pleura T2 Direct invasion of the pericardium (partial or full-thickness) T3 Direct invasion of the lung, the brachiocephalic vein, the superior vena cava, the chest wall, the phrenic nerve and/or hilar (extrapericardial) pulmonary vessels T4 Direct invasion of the aorta, arch vessels, the main pulmonary artery, the myocardium, the trachea or the oesophagus I  T1N0M0  I, IIA, IIB, III  II  T2N0M0  III  IIIA  T3N0M0  III  IIIB  T4N0M0  III  IVA  T any N0,1 M0,1a  IVA, IVB  IVB  T The final pathological examination leads to a final histological diagnosis and staging of the tumour, based on the WHO classification and the Masaoka-Koga system, respectively (Tables 1  and 3 ). Staging according to the proposed IASLC/ITMIG TNM system is optional [V, C] . Given the potential heterogeneity of postoperative radiotherapy
Current practices for postoperative mediastinal radiotherapy are highly variable and there is paucity of prospective, multicentre evidence. The global trend over the past years has been towards a less frequent use of postoperative radiotherapy in thymoma, and to keep it in reserve for high-risk cases (Table 5 ) [14] [15] [16] . This is based on recent reports from large databases [6, 7, [42] [43] [44] [45] , as well as pooled analyses of retrospective studies [46] , indicating:
• the absence of survival benefit after radiotherapy in stage I thymoma, or after R0/1 resection of stage II-III thymoma [7, 42, 43] ;
• a similar rate of recurrence in patients who received postoperative radiotherapy or not, after complete resection of thymoma [46] ; and
• a recurrence-free survival (RFS) and OS benefit with postoperative radiotherapy after resection of thymic carcinoma [7, 44, 45] .
Stage and completeness of resection are thus the most relevant criteria in the decision making, followed by histology [IV, B] . Those factors are the most significant predictors of RFS [4] [5] [6] [7] [28] [29] ; however, one must take into account that retrospective analyses are likely to be biased, since postoperative radiotherapy is most likely administered in patients with incomplete resection or high-grade tumours. Therefore, the absence of survival differences may then suggest that postoperative radiotherapy reduced or overcame the risk of recurrence in those patients. Another point to consider is that recurrences of thymic epithelial tumours occur outside the mediastinum in more than 60% of cases [47] . The development of the TNM system leads to redefinition of subsets of patients, based especially on the T descriptors, that may help to clarify which patients benefit from postoperative radiotherapy. Meanwhile, the grouping of Masaoka-Koga stage I, IIA, IIB and some stage III tumours in one single T1 category must be assessed in dedicated studies. Current evidence for postoperative radiotherapy in thymic epithelial tumours support the use of:
• 3D conformal radiotherapy or intensity-modulated radiation therapy targeted to the tumour bed, keeping at-risk thoracic organs within accepted safe constraints [IV, A];-clinical target volume includes the whole thymic space, the tumour and its extensions and the anterior, superior and middle mediastinum [IV, A].
• a total dose of 45-50 Gy after complete resection, 50-54 Gy after R1 resection, with a boost to areas of likely residual disease (as mentioned above, surgical clips may then be useful to define the target volume) [IV, B] ; however, the optimal postoperative dose/fractionation is still to be defined; and
• conventional fractionation scheme consisting of daily doses of thymomas. Postoperative radiotherapy is not indicated after complete resection of Masaoka-Koga stage I thymoma [II, E]. One randomised trial including 29 patients compared postoperative radiotherapy versus surgery alone in this setting, and failed to show any differences in patient outcome [50] .
Postoperative radiotherapy is not recommended after complete resection of stage II thymoma [IV, C]. In the ITMIG database, cumulative incidence of mediastinal or extramediastinal recurrence was only 8% at 10 years ( thymic carcinomas. Since thymic carcinomas do present with frequent and early locoregional and systemic recurrences after incomplete surgery [3, 7, 28, 44, 45] , postoperative chemotherapy may be considered as an option in stage II/III/IV thymic carcinomas, especially if not delivered as induction treatment (Table 5 ) [14] [15] [16] .
management of advanced disease
If complete resection is deemed not to be achievable upfront on the basis of imaging studies, as it is frequently the case in Masaoka-Koga stage III/IVA tumours (classified as stage IIIA/ T3, IIIB/T4, /IVA in the IASLC/ITMIG TNM proposed system), a biopsy should be carried out, followed by primary/induction chemotherapy as part of a curative-intent sequential strategy that integrates subsequent surgery or radiotherapy [14] [15] [16] . (Table 6 ) [66] [67] [68] [69] [70] [71] . No randomised studies have been conducted and which regimen should be considered standard remains unknown. Multiagent combination regimens and anthracycline-based regimens appear to have improved response rates compared with etoposide-based regimens [59, 60, 72] . Combination of cisplatin, doxorubicin and cyclophosphamide is preferred [III, B] . Combination of carboplatin and paclitaxel is an option for thymic carcinoma [69, 71] [III, B]. Surgery or radiotherapy is possible in rare and selected metastatic cases, without proven outcome benefit [IV, C].
Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A]; adapted criteria for pleural lesions include the use of the short axis as the measurement plane and the unidimensional measurement of two pleural tumour sites at three different levels [73] .
recurrences
Recurrences of thymic epithelial tumours are not uncommon (∼10%-15% of all-stage resected tumours) and should be managed according to the same strategy as newly diagnosed tumours [IV, A]. The average time-to-recurrence in completely resected thymic tumours is 5 years (with a range of 3-7 years). Complete resection of recurrent lesions represents a major predictor of favourable outcome [74] [75] [76] , and surgery is then recommended in the case of resectable lesion. Of note, histological switch from lymphocytic lesions to more epithelial tumours has been reported, and may be related to tumour heterogeneity, as well as the effect of previous corticosteroid and chemotherapy treatment [74] .
In non-resectable recurrences, several consecutive lines of chemotherapy may be administered when the patient presents with tumour progression (Table 6 ). The re-administration of a previously effective regimen should be considered [IV, B], especially in case of previous response, late occurring recurrence and, for anthracyclines, a patient in a good medical condition who has not received cumulative doses precluding the safe delivery of at least three additional cycles [77] . Of note, the risk of cardiac toxicity is further increased in patients having received previous mediastinal radiotherapy. Participation to clinical trials is recommended.
Preferred regimens for second-line treatment include carboplatin plus paclitaxel [69] , and platin plus etoposide [67] [III, B]; capecitabine plus gemcitabine is an option (Table 6) [III, B] . These regimens were evaluated in dedicated phase II trials. -Consultation with a second pathologist or referral of the case to a thymic tumour pathology panel is recommended whenever there is any diagnostic difficulty.
-Oncogenetic assessment should be carried out in case of familial thymic epithelial tumour, looking especially at MEN1.
Imaging and diagnostic tests
-Thymoma is the first diagnosis to consider when facing a mediastinal mass associated with autoimmune disease [IV, A].
-The diagnosis of any thymic epithelial tumour relies on making the differential diagnosis with other anterior mediastinal tumours and non-malignant thymic lesions. 
personalised medicine
Molecular characterisation of thymic epithelial tumours indicates the occurrence of chromosomal aberrations, altered DNA methylation and deregulated expression of cancer-related genes, such as CDKN2, MGMT, FOXC1, IGF-1R [81] ; some of those alterations and gene expression signatures were reported to associate preclinically with the efficacy of some targeted agents, or to predict recurrence or survival of patients [81, 82] .
Personalised medicine approaches in thymic malignancies are ultimately hampered by the limited amount of available research to identify reliable, validated molecular markers with prognostic or predictive value. However, the recent identification of molecular alterations occurring in the KIT, vascular endothelial growth factor receptors (VEGFRs) and mammalian target of rapamycin (mTOR) signalling pathways, may lead to consideration-in an off-label setting-of the use of targeted agents for the treatment of refractory thymic malignancies.
targeting of KIT
While KIT is overexpressed in 80% of thymic carcinomas, KIT gene mutations are found only in 9% of cases, consisting of mutations observed in gastrointestinal stromal tumours or melanomas (V560del, L576P), or restricted to thymic carcinomas (H697Y, D820E) [81] . Responses were reported with the use of KIT tyrosine kinase inhibitors (TKIs) imatinib, sunitinib or sorafenib, mostly in single-case observations [59] . KIT-mutant tumours are not uniformly sensitive to imatinib, based on the clinical and/or the preclinical evidence in thymic carcinoma targeting mammalian target of rapamycin mTOR is emerging as a potential target in thymic epithelial tumours, following tumour responses observed in phase I trials [87] . Everolimus was evaluated in thymic epithelial tumours in a recently reported phase II trial reporting on a 22% response rate, as well as a 93% DCR [88] . Everolimus may, therefore, represent an off-label option for refractory tumours [III, B].
follow-up and long-term implications
No prospective data are available to build recommendations about post-treatment oncological follow-up of patients. While a relapse might still be treatable in a curative-intent, patients should benefit from a regular radiological assessment. Based on expert consensus, and data of cumulative incidence of recurrences over time [28] , the proposals are the following [V, C]:
• baseline thoracic CT scan 3-4 months after surgery • for completely resected stage I/II thymomas: CT scan every year for 5 years, then every 2 years
• for stage III/IV thymomas, thymic carcinoma or after R1-2 resection: CT scan every 6 months for 2 years, then annually 
methodology
These clinical practice guidelines were developed in accordance with the ESMO standard operating procedures for clinical practice guidelines development. The relevant literature has been selected by the expert authors, using the Medline database, as well as abstracts lists from major surgery, medical oncology and thoracic oncology meetings, over the past 20 years. A summary of recommendations is presented in Table 7 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 8 [89] . Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty. This manuscript has been subjected to an anonymous peer review process.
acknowledgements
The authors thank Benjamin Besse (Gustave Roussy, Villejuif, France) for reviewing the manuscript. NG thanks all investigators of the RYTHMIC network for their input on the French recommendations, which was valuable for the subsequent development of the present clinical practice guidelines.
conflict of interest
NG has reported consultancy from Amgen, Astra-Zeneca, BristolMyers Squibb, Boehringer Ingelheim, Eli-Lilly, Hoffmann-La Roche, Novartis, Pfizer, Teva. SP has provided consultancy, attended 
